In GC tumor-bearing mice, the combination of a PD-1 inhibitor and apatinib significantly increased CD4+ and CD8+ T cell infiltration in the TME, while reducing MDSCs, thereby boosting the effectiveness of immunotherapy (53). This evidence concerns the gene CD4 and neoplasm.